30710258|t|Intraoperative use of dexmedetomidine for the prevention of emergence agitation and postoperative delirium in thoracic surgery: a randomized-controlled trial.
30710258|a|PURPOSE: We investigated whether preventive use of dexmedetomidine during surgery was effective for reducing emergence agitation and postoperative delirium. METHODS: In this double-blind randomized-controlled trial, 143 patients undergoing thoracoscopic lung resection surgery were randomly assigned to the dexmedetomidine-sevoflurane (DEX-Sevo, n = 73) or sevoflurane (Sevo, n = 70) groups. Dexmedetomidine or saline administration was started after inducing anesthesia and continued until the end of surgery at a fixed dose (0.5 microg kg-1 hr-1). The primary endpoint was the incidence of delirium up until the end of postoperative day 3. Emergence agitation and postoperative delirium were measured with the Riker sedation agitation scale and the confusion assessment method, respectively. The secondary endpoints were serum cytokine and catecholamine levels. RESULTS: The DEX-Sevo group showed less frequent emergence agitation than the Sevo group (13% vs 35%, respectively; relative risk, 0.38; 95% confidence interval [CI], 0.18 to 0.79; P = 0.011) but the incidence of delirium after discharge from the postanesthesia care unit was not different (25% vs 25%, DEX-Sevo vs Sevo). Both pro- and anti-inflammatory cytokines were lower in the DEX-Sevo group than in the Sevo group. Nevertheless, the interleukin (IL)6/IL10 ratio (median difference, 5.8; 95% CI,1.8 to 10.0; P = 0.012) and IL8/IL10 ratio (median difference, 0.8; 95% CI, 0.2 to 1.3; P = 0.007) were higher in the DEX-Sevo group than in the Sevo group, indicating a pro-inflammatory cytokine balance in the DEX-Sevo group. Norepinephrine and epinephrine levels were lower in the DEX-Sevo group than in the Sevo group (both, P < 0.001). CONCLUSIONS: Intraoperative dexmedetomidine reduced emergence agitation but not postoperative delirium in patients undergoing thoracic surgery. Dexmedetomidine seemed to affect emergence agitation through catecholamines, but not through an anti-inflammatory action. Trial registration Clinical Research Information Service (KCT 0001877); registered 7 April, 2016.
30710258	22	37	dexmedetomidine	Chemical	MESH:D020927
30710258	60	79	emergence agitation	Disease	MESH:D000071257
30710258	84	106	postoperative delirium	Disease	MESH:D000071257
30710258	210	225	dexmedetomidine	Chemical	MESH:D020927
30710258	268	287	emergence agitation	Disease	MESH:D000071257
30710258	292	314	postoperative delirium	Disease	MESH:D000071257
30710258	379	387	patients	Species	9606
30710258	466	481	dexmedetomidine	Chemical	MESH:D020927
30710258	482	493	sevoflurane	Chemical	MESH:D000077149
30710258	495	498	DEX	Chemical	MESH:D003915
30710258	499	503	Sevo	Chemical	MESH:D000077149
30710258	516	527	sevoflurane	Chemical	MESH:D000077149
30710258	529	533	Sevo	Chemical	MESH:D000077149
30710258	551	566	Dexmedetomidine	Chemical	MESH:D020927
30710258	751	759	delirium	Disease	MESH:D003693
30710258	801	820	Emergence agitation	Disease	MESH:D000071257
30710258	825	847	postoperative delirium	Disease	MESH:D000071257
30710258	886	895	agitation	Disease	MESH:D011595
30710258	1001	1014	catecholamine	Chemical	MESH:D002395
30710258	1036	1039	DEX	Chemical	MESH:D003915
30710258	1040	1044	Sevo	Chemical	MESH:D000077149
30710258	1072	1091	emergence agitation	Disease	MESH:D000071257
30710258	1101	1105	Sevo	Chemical	MESH:D000077149
30710258	1236	1244	delirium	Disease	MESH:D003693
30710258	1326	1329	DEX	Chemical	MESH:D003915
30710258	1330	1334	Sevo	Chemical	MESH:D000077149
30710258	1338	1342	Sevo	Chemical	MESH:D000077149
30710258	1364	1376	inflammatory	Disease	MESH:D007249
30710258	1405	1408	DEX	Chemical	MESH:D003915
30710258	1409	1413	Sevo	Chemical	MESH:D000077149
30710258	1432	1436	Sevo	Chemical	MESH:D000077149
30710258	1480	1484	IL10	Gene	3586
30710258	1551	1554	IL8	Gene	3576
30710258	1555	1559	IL10	Gene	3586
30710258	1641	1644	DEX	Chemical	MESH:D003915
30710258	1645	1649	Sevo	Chemical	MESH:D000077149
30710258	1668	1672	Sevo	Chemical	MESH:D000077149
30710258	1697	1709	inflammatory	Disease	MESH:D007249
30710258	1734	1737	DEX	Chemical	MESH:D003915
30710258	1738	1742	Sevo	Chemical	MESH:D000077149
30710258	1750	1764	Norepinephrine	Chemical	MESH:D009638
30710258	1769	1780	epinephrine	Chemical	MESH:D004837
30710258	1806	1809	DEX	Chemical	MESH:D003915
30710258	1810	1814	Sevo	Chemical	MESH:D000077149
30710258	1833	1837	Sevo	Chemical	MESH:D000077149
30710258	1891	1906	dexmedetomidine	Chemical	MESH:D020927
30710258	1915	1934	emergence agitation	Disease	MESH:D000071257
30710258	1943	1965	postoperative delirium	Disease	MESH:D000071257
30710258	1969	1977	patients	Species	9606
30710258	2007	2022	Dexmedetomidine	Chemical	MESH:D020927
30710258	2040	2059	emergence agitation	Disease	MESH:D000071257
30710258	2068	2082	catecholamines	Chemical	MESH:D002395
30710258	2108	2120	inflammatory	Disease	MESH:D007249
30710258	Cotreatment	MESH:D000077149	MESH:D020927
30710258	Cotreatment	MESH:D003915	MESH:D020927
30710258	Negative_Correlation	MESH:D000077149	MESH:D007249
30710258	Positive_Correlation	MESH:D000077149	3586
30710258	Positive_Correlation	MESH:D000077149	3576
30710258	Negative_Correlation	MESH:D003915	MESH:D009638
30710258	Positive_Correlation	MESH:D003915	3576
30710258	Association	MESH:D000077149	MESH:D000071257
30710258	Negative_Correlation	MESH:D003915	MESH:D007249
30710258	Positive_Correlation	MESH:D003915	3586
30710258	Negative_Correlation	MESH:D020927	MESH:D000071257
30710258	Negative_Correlation	MESH:D003915	MESH:D000071257
30710258	Cotreatment	MESH:D000077149	MESH:D003915
30710258	Negative_Correlation	MESH:D003915	MESH:D004837

